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Abstract 39 
Osteosarcoma (OS) is a malignant tumor of mesenchymal origin that produces osteoid. 40 
Given that the prognosis varies considerably between dogs, we explored whether treatment 41 
could be tailored towards prognostic subgroups of patients.For the current study, individual 42 
patient data from five nonrandomized studies were combined. Based on a multivariable 43 
prognostic model, the 5-month mortality risk was estimated. Subsequently, in surgically 44 
treated dogs, we explored whether ‘any chemotherapy’ compared to no chemotherapy 45 
influenced their 5-month mortality risk. After adjustment for potential confounders the main 46 
effect of any chemotherapy was odds ratio 0.48 (95%CI 0.30; 0.78). Testing for 47 
chemotherapy by 5-month mortality risk interaction revealed that the effects of any 48 
chemotherapy decreased with increasing risk, P-value = 0.04, indicating that dogs with a 49 
lower risk of 5-month mortality benefited most from chemotherapy. Results from individually 50 
comparing carboplatin, cisplatin, doxorubicin and doxorubicin combination therapy to no 51 
chemotherapy, were similar in magnitude and direction. These results indicate that the main 52 
treatment effects of chemotherapy do not necessarily apply to all patients.  53 
  54 
MeSH/keywords: Canine; Personalized Medicine; Oncology, Bone tumour.55 
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Introduction 56 
Osteosarcoma (OS) is a malignant tumor of mesenchymal origin that produces osteoid. 57 
In dogs, OS most frequently occurs in large and giant breeds (Cooley and Waters, 1997; 58 
McNeill et al., 2007; Norrdin et al., 1989; Ru et al., 1998; Spodnick et al., 1992). Dogs that 59 
are treated with amputation have a median survival time of five months, with the majority 60 
succumbing to metastatic disease (Brodey and Abt, 1976; Straw and Withrow, 1996). Clinical 61 
studies have shown that on average survival in OS dogs can be extended by administrating 62 
chemotherapy (Bailey et al., 2003; Chun et al., 2005; Chun et al., 2000; Straw et al., 1991; 63 
Vail et al., 2002).  64 
 65 
(Boerman et al., 2012)In a recent Individual Patient Data Meta-Analysis (IPDMA), we 66 
identified baseline variables that were associated with survival in dogs with osteosarcoma 67 
(Schmidt et al., 2013). Such a prognostic model can be used to predict a dog’s risk of early 68 
mortality (Moons et al., 2012). This offers the possibility to identify subgroups of dogs 69 
according to their baseline prognosis and target treatment at those patients most likely to 70 
benefit. This can potentially prevent dogs from unnecessarily receiving treatment, which is 71 
relevant in terms of both costs and quality of life. Clearly, there is a need to obtain estimates 72 
of individualized treatment effects (Hayward et al., 2006; Kent et al., 2010; Rothwell and 73 
Warlow, 1999).  74 
 75 
In the current paper, (Schmidt et al., 2013), chemotherapy effects were individualized 76 
by determining whether dogs with a different 5-month mortality risk, reacted differently to 77 
chemotherapy treatment. Specifically, using an adapted version of the previously published 78 
prediction model (Schmidt et al., 2013), we first predicted a dog’s 5-month mortality risk 79 
based on age, weight, gender neuter status, serum alkaline phosphatase (SALP) level, breed, 80 
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and tumor location at time of surgery. Subsequently we evaluated what the effect was of “any 81 
chemotherapy” compared to no chemotherapy on the 5-month mortality incidence and if this 82 
effect differed between dogs with different predicted 5-month mortality risks. Finally, we 83 
repeated the analysis with separated groups for carboplatin, cisplatin, doxorubicin and 84 
doxorubicin combination therapy and estimated the effect on 5-month mortality incidence 85 
compared to dogs receiving no chemotherapy.  86 
 87 
Materials and Methods 88 
The effects of the different chemotherapeutics compared to no chemotherapy were 89 
determined using individual patient data (IPD). These IPD were used previously in an IPD 90 
meta-analysis (IPDMA) combining data of 20 studies to determine prognostic factors for 91 
early mortality in dogs with osteosarcoma (Schmidt et al., 2013). A detailed description of the 92 
data accrual can be found in the original publication (a review protocol is unavailable). 93 
Briefly, studies were collected via the Veterinary Society of Surgical Oncology (VSSO). In 94 
January 2012, a call for collaboration was sent out to VSSO members and other veterinary 95 
oncologic researchers. Data was deemed eligible if baseline patient characteristics of OS dogs 96 
and time to event (death or metastasis) were recorded. To reduce the possibility of publication 97 
bias (Easterbrook et al., 1991), published and unpublished studies were both eligible. All dogs 98 
in these studies were diagnosed with osteosarcoma. For the present analysis, dogs were 99 
excluded if they did not receive surgery; due to euthanasia (n = 197), who received limb-100 
sparing surgery (n = 41), who received an infrequently used chemotherapeutic protocol (n = 101 
13) or who received radiation therapy (n =11). Additionally, the study by Sottnik (Sottnik et 102 
al., 2010) only collected data on metastasis, not mortality, and was excluded. Data was 103 
available from 1295 dogs collected in 16 studies.  104 
 105 
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To answer our present questions, does chemotherapy effectiveness differ between dogs 106 
with different predicted 5-month mortality risk, we used the 1295 dogs to construct a logistic 107 
regression prediction model; predicting mortality at 5 months. Subsequently, from these 1295 108 
dogs (16 studies), studies were selected that included at least five dogs on no chemotherapy 109 
and at least five dogs treated with one of the interventions of interest (i.e., carboplatin, 110 
cisplatin, doxorubicin or doxorubicin combination therapy). Five studies fulfilled this 111 
criterion; of these 5 studies, two were previously published (Amsellem et al., 2014; 112 
Kirpensteijn et al., 2002; Kow et al., 2008). After excluding dogs that received lobaplatin 113 
chemotherapy (n = 27) 400 subjects remained. Regrettably, none of these 5 studies randomly 114 
allocated chemotherapy hence chemotherapy associations are presumably confounded; an 115 
issue that will be addressed later. We will first briefly describe how the logistic regression 116 
prediction model was derived (using the 1295 dogs). Second, we describe in detail how the 5-117 
month mortality risk was calculated for each individual dog. Third, we explain how 118 
individualized chemotherapy effect estimates were derived (based on the 400 dogs). Finally, a 119 
number of sensitivity analyses are discussed. Note that this study focused on 5-month 120 
mortality, because this is regarded as a clinical relevant endpoint (Brodey and Abt, 1976; 121 
Spodnick et al., 1992; Straw et al., 1991). 122 
 123 
Data analysis: prediction model 124 
Instead of using the Cox’s proportional hazards prediction model described in Schmidt 125 
et al., (2013) to predict an individual dog’s risk of dying at 5 months, the current analysis uses 126 
a prediction model based on a logistic regression model with random intercept for study. This 127 
prediction model used data from the previously described 1295 dogs and regressed a 5-month 128 
mortality indicator on the predictor’s gender, neuter status, tumor location (proximal humerus, 129 
distal femur or proximal tibia, distal radius, versus other locations), age (years, continuous), 130 
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weight (kg, continuous), breed (Rottweiler, Golden Retriever, Labrador Retriever, 131 
Greyhound, Doberman, mixed breeds, versus other breeds) and serum alkaline phosphatase 132 
(SALP, using study specific cut-off values for high and normal SALP levels). Chemotherapy 133 
was included as a nuisance variable and was set to zero (no chemotherapy) when predicting 134 
the 5-month mortality risk. As in the original publication, all predictors were predefined and 135 
no model selection was used (Schmidt et al., 2013). However, linearity of the continuous 136 
predictors was assessed by comparing a model (using a likelihood ratio test) with restricted 137 
cubic splines (5 knots) to a model forcing linearity. Additionally, restricted cubic spline plots 138 
were created to visually inspect linearity. Besides, SALP which was dichotomized, no 139 
deviations from linearity were observed (Refer to Table 1 for the derived prediction model 140 
based on 1295 dogs with ). additional(Chatfield, 1995) 141 
 142 
In the following section, the performance of this prediction model is described. 143 
Discrimination, measured as a c-statistic, was 0.63 (95%CI 0.59; 0.67) indicating that the 144 
model could not perfectly discriminate survivors from those that died. However, calibration-145 
in-the-large was 0.0005, indicating that the predicted and observed 5-month mortality risk 146 
agreed on average (p-value = 0.99). The calibration slope of 0.77 (95%CI 0.55; 1.00), showed 147 
that the predicted risk was too small for dogs with a low observed risk and too large for dogs 148 
with a higher observed risk, however these discrepancies were small (Appendix Figure A). 149 
All performance measures were corrected for optimism using 100 bootstrap samples 150 
(Steyerberg, 2009; Steyerberg et al., 2010).  151 
 152 
In these 1295 dogs about 8% of the data was missing, information on 5-month 153 
mortality was missing for 4.2% of the observations and chemotherapy for 2.4% of the 154 
observations (see for more details Schmidt et al., 2013). Univariable tests showed that 155 
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missingness was associated with observed variables (results available from the first author) 156 
biasing a complete case analysis (Altman and Bland, 2007; Rubin, 1976). To adjust bias due 157 
to missing data, this dependency was taken into account by imputing missing observation  158 
using the aregImpute algorithm from the Hmisc package version 3.13-0 (Harrell, Jr. and 159 
Dupont, 2013). The aregImpute algorithm was implemented using 10 burn-in iterations, 100 160 
approximate bootstrap samples and predictive mean matching. To get correct estimates of the 161 
standard errors 100 imputed datasets were created (i.e., multiple imputation). Results over all 162 
100 imputed datasets were pooled using Rubin’s rules (Little and Rubin, 2002; Marshall et al., 163 
2009) 164 
 165 
Data analysis: predicting 5-month mortality 166 
An individual dogs’ risk of 5-month mortality, under no chemotherapy, was predicted 167 
using the coefficient presented in Table 1 and by setting the chemotherapy to zero (no 168 
chemotherapy):  169 
 170 
𝑙𝑜𝑔𝑖𝑡(5 − 𝑚𝑜𝑛𝑡ℎ 𝑚𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 𝑟𝑖𝑠𝑘) = 𝑙𝑜𝑔𝑖𝑡(?̂?𝑖) = ?̂?0 + ?̂?1 ∗ 𝑐ℎ𝑒𝑚𝑜𝑡ℎ𝑒𝑟𝑎𝑝𝑦(0) + … +171 
 ?̂?𝑗𝑥𝑖𝑗 [equation 1] 172 
 173 
Here ?̂?𝑖 indicates an individuals’ risk of being dead at 5 months. ?̂?𝑗represent the coefficient 174 
for the 𝑗𝑡ℎ variable presented in Table 1, note that 𝑗 ≠ {0,1,2,3,4,5}. Finally, 𝑥𝑖𝑗 represents an 175 
individuals’ value for the 𝑗𝑡ℎ variable. Note, that this is equal to calculating the linear 176 
predictors conditional on no chemotherapy. ,For these predictions, the random intercept (from 177 
the logistic regression model) was ignored because in clinical practice this prediction model 178 
would not be limited to the studies included in our meta-analysis. The logit(5-month mortality 179 
risk) can vary from minus to plus infinity, with zero referring to a risk of 50%. This logit(5-180 
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month mortality risk) can be transformed to the 5-month mortality risk, bounded between 0 181 
and 1, by the following equation:  182 
 183 
?̂?𝑖 =
1
1+𝑒−𝑙𝑜𝑔𝑖𝑡(?̂?𝑖)
     [equation 2]; see Table 1 for an example.  184 
 185 
Applying equation 2 results in an estimate of the risk of 5-month mortality given that 186 
the patient did not receive chemotherapy. Note that because the logit(5-month mortality risk) 187 
is expected to be linearly related with the outcome this was included in all models. Where 188 
appropriate the logit(5-month mortality risk) was transformed to the 5-month mortality risk 189 
using equation 2; for example when graphing results.  190 
 191 
Data analysis: estimating chemotherapy effectiveness 192 
As indicated previously, first the association of “any chemotherapy” compared to no 193 
chemotherapy with 5-month mortality was estimated. If this association was significant we 194 
determined how the different chemotherapeutics carboplatin, cisplatin, doxorubicin or 195 
doxorubicin combination compared to no chemotherapy. These analyses used the previously 196 
defined subset of 400 subjects, collected by combining 5 studies (see Appendix Table A). 197 
Depending on the comparison, a different subset of these 5 studies was used (see Appendix 198 
Tables B through E): for any chemotherapy all studies were used, similarly for doxorubicin 199 
combination all studies were used, for carboplatin the study by Kirpensteijn was excluded, for 200 
doxorubicin the studies by Kirpensteijn and Amsellum were excluded and finally for the 201 
cisplatin comparison only the study by Bacon was used. This selection was based on whether 202 
the studies included any dog on the mentioned chemotherapeutic and prevents bias due to 203 
study specific influences.  204 
 205 
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Before determining whether chemotherapy effects differed between dogs with a 206 
different logit(5-month mortality risk) we first estimated the main effect of chemotherapy 207 
(i.e., a model regressing 5-month mortality on chemotherapy and co-variables without an 208 
interaction term with chemotherapy). These main effects provide an estimate of the average 209 
effect of chemotherapy and were derived using a logistic regression model including a 210 
random intercept for study. Specifically, a model was fitted, regressing 5-month mortality on 211 
the chemotherapy variable and a random intercept for study. A second model additionally 212 
included gender, neuter status, tumor locations, age, weight and SALP. The third model 213 
additionally adjusted for breed. These variables were included in an attempt to adjust for 214 
confounding and were selected based on prior knowledge (Hernan et al., 2002). To reduce the 215 
risk of residual confounding(Bland and Altman, 1995), no model reduction strategy was 216 
employed (i.e., backward selection) and no differentiation was made between predictors of the 217 
outcome and confounders.  218 
 219 
After determining the main effects, we explored whether chemotherapy effectiveness 220 
depended on logit(5-month mortality risk) by including a chemotherapy by logit(5-month 221 
mortality risk) interaction term in the model.  222 
 223 
𝑙𝑜𝑔𝑖𝑡(𝑝𝑟𝑜𝑏[𝑦𝑖𝑠 = 1])224 
= ?̂?0𝑠 +  ?̂?1 ∗ 𝑐ℎ𝑒𝑚𝑜𝑡ℎ𝑒𝑟𝑎𝑝𝑦 + ?̂?2 ∗ 𝑙𝑜𝑔𝑖𝑡(?̂?𝑖 ) + ?̂?3 ∗ 𝑐ℎ𝑒𝑚𝑜𝑡ℎ𝑒𝑟𝑎𝑝𝑦225 
∗ 𝑙𝑜𝑔𝑖𝑡(?̂?𝑖 ) + 𝜖𝑖𝑠 226 
 227 
Here 𝑦𝑖 represent an individual's mortality status at 5-months. Let ?̂?1represent the 228 
estimated association of chemotherapy compared to no chemotherapy when all co-variables 229 
are zero [i.e., when the logit(5-month mortality risk) = 0], ?̂?2 the association of logit(5-month 230 
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mortality risk) when a patients does not receive chemotherapy, and ?̂?3 the association of the 231 
chemotherapy by logit(5-month mortality risk) interaction term. ?̂?3 indicates how much the 232 
association of chemotherapy changes per unit increase or decrease of the logit(5-month 233 
mortality risk). In the absence of interaction, ?̂?3 becomes zero and could be omitted. Note that 234 
epsilon indicates the amount of residual error from the intercept ?̂?0𝑠 per individual 𝑖 and per 235 
study 𝑠.(Arbogast et al., 2008). Using these estimates an individualized effect of 236 
chemotherapy can be calculated:  237 
 238 
𝑂?̂?𝑖 = 𝑒
?̂?1∗𝑐ℎ𝑒𝑚𝑜𝑡ℎ𝑒𝑟𝑎𝑝𝑦(1)+?̂?3∗𝑐ℎ𝑒𝑚𝑜𝑡ℎ𝑒𝑟𝑎𝑝𝑦(1)∗𝑙𝑜𝑔𝑖𝑡(𝑝𝑖 )     [equation 3] 239 
 240 
Here OR represent the estimated odds ratio of chemotherapy for the 𝑖𝑡ℎ individual. This 241 
methodology has been previously applied in human medicine most notably in the SYNTAX 242 
trial (Farooq et al., 2013; van Klaveren D. et al., 2015). Note, that 𝑙𝑜𝑔𝑖𝑡(?̂?𝑖 ) =  𝑙𝑜𝑔𝑖𝑡(5 −243 
𝑚𝑜𝑛𝑡ℎ 𝑚𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 𝑟𝑖𝑠𝑘) and is calculated using equation 1.  244 
 245 
For the subset of 400 dogs on average 12.6% of the information was missing; 246 
specifically, 5-month mortality 9%, chemotherapy 7.5%, tumor location 9.5%, gender 5.3%, 247 
neuter status 5.3%, age 6.5%, weight 26.3%, high SALP 57,5% and breed 4.5%, (see Table 2 248 
for an overview). Again missing values were imputed as previously described.  249 
 250 
Data analysis: sensitivity analyses 251 
In the following section we describe a few sensitivity analyses evaluating the 252 
appropriateness of assumptions made.  253 
 254 
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Throughout a logistic regression model was used including a random intercept for 255 
study. Such a model assumes that the random intercept can sufficiently be described by a 256 
normal distribution. To evaluate this assumption a regular logistic regression model was used 257 
including study as a categorical factor, which does not assume any parametric distribution; 258 
results did not differ (see Appendix Table F).  259 
 260 
In all 5 studies included, chemotherapy was not allocated randomly. Therefore it is 261 
possible that dogs did not receive chemotherapy because of a worse prognosis, which would 262 
overestimate any beneficial effects of chemotherapy. To explore this, all analyses were 263 
repeated using the subset of patients that survived the first month (30 days). While, this 264 
analysis potentially decreases bias, precision was decreased because 22 % of the events 265 
occurred in the first month. 266 
  267 
Previously, we implicitly assumed that the association of chemotherapy by logit(5-268 
month mortality risk) interaction term with the outcome was linear. The appropriateness of 269 
this assumption was evaluated by comparing a model with a restricted cubic spline (with five 270 
knots) for the interaction term to a model without splines, using a likelihood ratio test. 271 
Additionally, a model was compared that categorized the logit(5-month mortality risk) in 272 
quintiles. No significant deviations from linearity were observed.  273 
  274 
All tests were applied using a significance level of 0.05, estimates are presented as 275 
odds ratios (OR) with 95% confidence intervals (95%CI). Analyses were carried out using the 276 
R statistical package for windows version 3.0.2 (R Development Core Team, 2013), the lme4 277 
package version 1.1-7 for random effect models (Bates et al., 2012), and the metaphor 278 
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package (Viechtbauer, 2010). R codes are available upon request with the first author. A 279 
PRISMA checklist is included as appendix.  280 
 281 
Results 282 
Baseline characteristics of the 406 included dogs are presented in Table 2, after 283 
surgical amputation 227 received additional chemotherapy and 143 dogs did not, of these 87 284 
were dead after 5 months. Information on chemotherapy was missing for 30 subjects and 5-285 
month mortality for 36 subjects. In general, dogs not receiving chemotherapy were older, 286 
weighed less, were more often female, neutered and had high SALP. The range of the logit(5-287 
month mortality risk) was -1.91 to 1.03. Baseline characteristics for the other comparisons 288 
(carboplatin, cisplatin, doxorubicin and doxorubicin combination) are presented in Appendix 289 
Tables B through E.  290 
 291 
The crude main effect estimates of “any chemotherapy” versus no chemotherapy on 5-292 
month mortality was OR 0.43 (95%CI 0.27; 0.70). After adjustment for potential confounders 293 
the OR was 0.48 (95%CI 0.30; 0.78), for details refer to Table 3. Results for the other 294 
comparisons were similar; with the possible exception of the cisplatin effect, which was non-295 
significant (Table 3).  296 
 297 
Testing for chemotherapy by logit(5-month mortality risk) interaction revealed that the 298 
effects of any chemotherapy (compared to no chemotherapy) decreased with increasing 299 
logit(5-month mortality risk, Table 4); interaction OR 3.41 (95%CI 1.08; 10.79) P-value = 300 
0.04. Figure 1 depicts how the OR of chemotherapy changes with logit(5-month mortality) 301 
and 5-month mortality (i.e., on the risk scale) and  shows that dogs’ with a 5-month mortality 302 
risk of approximately 0.43 or less benefit from chemotherapy. For dogs’ at a higher risk, 303 
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chemotherapy effectiveness is uncertain because an OR of 1 is included in the 95% 304 
confidence interval. Results for the other comparisons and study specific estimates were 305 
consistent with the overall ORs presented here,(Figures 2 and 3).  306 
 307 
 The results of the sensitivity analysis of excluding those subjects who died within the 308 
first month are depicted in Table 4. The main effect estimates were closer to the null than in 309 
the entire sample; OR of “any chemotherapy” 0.81 (95%CI 0.47; 1.39). Interaction effects 310 
were also closer to the 1: OR 2.44 (95%CI 0.66; 8.97). The magnitude and direction of these 311 
interaction effects were in agreement with those estimated in the entire sample. Similar and 312 
consistent results were found for the individual comparisons (data not shown). 313 
 314 
Discussion  315 
This study showed that dogs with osteosarcoma and a relatively low 5-month mortality 316 
risk (< 0.43) benefited, more from “any chemotherapy” compared to no chemotherapy than 317 
those with a higher risk. Results from individually comparing the chemotherapeutics, 318 
carboplatin, cisplatin, doxorubicin or doxorubicin combination therapy, to no chemotherapy 319 
were similar in direction and magnitude, indicating consistency, however interaction effects 320 
did not attain significance.  321 
 322 
Previous clinical studies showed that the effect of chemotherapy might be modified by 323 
other factors. One of the clearest examples of this in dogs is the synergistic effect between 324 
immunotherapy and chemotherapy (MacEwen and Kurzman, 1996; Vail et al., 1995). To the 325 
best of our knowledge, our study is the first to explore whether chemotherapy effects vary 326 
according to baseline mortality risk (using multiple variables).  327 
 328 
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The current study has some limitations. First, only data from nonrandomized studies 329 
were available. Therefore, chemotherapy effect estimates could be biased due to unobserved 330 
and residual confounding. To explore this, a sensitivity analysis was performed, including 331 
dogs who survived the first month. Results in this subgroup showed estimates closer to an OR 332 
of 1.Interaction effects remained in the same direction and of the same magnitude as the 333 
interaction effects using the entire sample, implying consistency. Furthermore, using an 334 
independent validation cohort study (jointly submitted) these results were replicated. Despite 335 
these reassuring results, we acknowledge that in lieu of randomization our results can possibly 336 
still be confounded. This shortcoming could be remedied in the future by replicating our 337 
results using (historical) RCT data. A second issue is that the prediction model was derived 338 
including the subset of studies which was used to test for the presence of an interaction. 339 
However, a recent simulation study showed that such an internally developed model only 340 
deviated slightly from externally derived models (Burke et al., 2014). Additionally, we note 341 
that results were replicated using an independent cohort study (see manuscript 2 jointly 342 
submitted). To some including, non-significant predictors may seem erroneous. Perhaps 343 
surprisingly, numerous studies have shown that focussing on significant predictors results in 344 
an overfitted model which does not generalize well to other settings (Steyerberg, 2009; 345 
Steyerberg et al., 1999; Steyerberg et al., 2011; Steyerberg et al., 2010). To remedy this, it has 346 
been suggested to use prior knowledge to select relevant predictors, which we have 347 
implemented here. Regardless, a validation study (see manuscript 2 jointly submitted) showed 348 
that our choice of non-significant predictors was appropriate to predict early OS mortality an 349 
independent setting.  More importantly, we note that the discriminatory ability of the 350 
prediction model was limited (c-statistic 0.63). However, calibration (i.e., how well the 351 
predicted risk matched the observed risk) was very reasonable. For the current purpose, 352 
predicting chemotherapy effects in individual dogs, good calibration is perhaps more relevant. 353 
16 
 
Another limitation is that a number of observations were missing. Instead of focussing on 354 
complete cases we tried to address this problem using multiple imputation. While most 355 
studies suffer from missing data and using imputation methods is likely to decrease bias it 356 
possible that results were biased. We did not perform a comparison with a complete case 357 
analysis (dropping missing values), because our analyses showed missing data to associated 358 
with observed variables invalidating a complete case analysis. Furthermore, too many subjects 359 
(n = 231; 58%) would be excluded to allow a proper analysis.(Carpenter and Bithell, 360 
2000).(Sofroniou and Hutcheson, 2002)(Sofroniou and Hutcheson, 2002) 361 
RegardlessSimilarly, due to the small sample size available we did not adjust for multiple 362 
testing. Additionally, in the present analyses we only focused on beneficially effects (or its 363 
absence), ideally adverse events should also be evaluated. Unfortunately, this was not 364 
systematically measured in the original studies included in this IPD meta-analysis. Finally, 365 
some researchers prefer absolute effect measure such as risk differences over odds ratios. 366 
Presumably, the risk difference is preferred because, when the outcome incidence is low, the 367 
odds ratio can be large while the risk difference is small. For example, if the incidence in an 368 
unexposed group of subjects is 0.05 and 0.01 in the exposed the odds ratio is 5.21 while the 369 
risk difference is only 0.04. However, 5-month mortality in OS dogs is very common (24% in 370 
our sample) making this distinction less relevant. Nevertheless, the risk difference can be 371 
calculated from the equations presented.  (Kent and Hayward, 2007) (Sun et al., 2011) 372 
 373 
Conclusions 374 
In conclusion, surgically treated dogs with osteosarcoma which have a relatively low 375 
risk of 5-month mortality might benefit most from additional chemotherapy. 376 
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Figure captions 418 
 419 
Figure 1. Estimated effect of any chemotherapy compared to no chemotherapy on 5-420 
month mortality in surgically treated dogs with osteosarcoma. 421 
 422 
[figure 1] 423 
 424 
Figure shows the odds ratio (OR) of any chemotherapy treatment (solid line) with 95% 425 
confidence intervals (dotted lines) for dogs with different predicted risks of 5-month 426 
mortality. The horizontal solid line indicates a neutral OR of 1.00. At the bottom a histogram 427 
is given, corresponding to the patient frequencies of the x-axis measurement.  428 
 429 
Figure 2. Estimated effects of four different chemotherapeutics compared to no 430 
chemotherapy on 5-month mortality in surgically treated dogs with osteosarcoma. 431 
 432 
[figure 2] 433 
 434 
Figure shows the odds ratio (OR) of carboplatin, cisplatin, doxorubicin or doxorubicin 435 
combination therapy compared to no chemotherapy (solid line) with 95% confidence intervals 436 
(dotted lines) for dogs with different predicted risks of 5-month mortality . The horizontal 437 
solid line indicates a neutral OR of 1.00. At the bottom of each graph a histogram is given, 438 
corresponding to the patient frequencies of the x-axis measurement. 439 
 440 
Figure 3. Forest plot of the estimated effect of any chemotherapy compared to no 441 
chemotherapy on 5-month mortality in surgically treated dogs with osteosarcoma. 442 
 443 
[figure 3] 444 
 445 
The left panel shows the main effects, excluding an interaction, the right panel shows the 446 
interaction effects. Effects are depicted as odds ratio (OR) with 95% confidence interval, and 447 
pooled across studies using fixed effects (random intercept only) and random effects (random 448 
intercept and random slope) models. Interaction effect is per unit increase in the logit(5-month 449 
mortality risk). Heterogeneity measured as the tau-squared was 0.01 95%CI (-0.30; 0.33) for 450 
the main effect and 0.01 95%CI (-0.19; 0.19) for the interaction effect.  451 
 452 
  453 
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